Targets › NR1H4
11 programs from 11 companies in 12 trials: 7 Phase 2, 3 Phase 4, 2 Phase 3; Gastroenterology, Oncology, Immunology; next expected readout Dec 2026.
Ligand-activated transcription factor. Receptor for bile acids (BAs) such as chenodeoxycholic acid (CDCA), lithocholic acid, deoxycholic acid (DCA) and allocholic acid (ACA). (UniProt, Q96RI1)
Open in Phaseline: the race on NR1H4, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Yongquan Shi | Ursodiol Bile acid receptor FXR agonist | NR1H4 | Phase 4 | Gastric Intestinal Metaplasia | – |
| Ain Shams University | Ursodiol Bile acid receptor FXR agonist | NR1H4 | Phase 4 | Non Alcoholic Fatty Liver Diseases (NAFLD) | – |
| Peking Union Medical College Hospital | Ursodiol Bile acid receptor FXR agonist | NR1H4 | Phase 4 | Primary Biliary Cholangitis | – |
| Hospital General Universitario de Alicante | Ursodiol Bile acid receptor FXR agonist | NR1H4 | Phase 3 | Acute Pancreatitis Due to Gallstones | Jul 2027 |
| Xijing Hospital of Digestive Diseases | Ursodiol Bile acid receptor FXR agonist | NR1H4 | Phase 3 | Primary Biliary Cholangitis (PBC) | Dec 2035 |
| Jinling Hospital, China | Ursodiol Bile acid receptor FXR agonist | NR1H4 | Phase 2 | Kidney Cancer | Dec 2026 |
| Tanta University | Obeticholic Acid Bile acid receptor FXR agonist | NR1H4 | Phase 2 | Non-alcoholic Steatohepatitis | Dec 2026 |
| Eli Lilly | LY4395089 Farnesoid X receptor (FXR) agonist | NR1H4 | Phase 2 | Colitis, Ulcerative; Crohn Disease | Jun 2027 |
| National Cancer Institute (NCI) | Obeticholic Acid Bile acid receptor FXR agonist | NR1H4 | Phase 2 | Barrett Esophagus | Sep 2027 |
| University Hospital, Montpellier | Ursodiol Bile acid receptor FXR agonist | NR1H4 | Phase 2 | Immune-Mediated Cholestasis | Jan 2028 |
| Gilead Sciences | Cilofexor Bile acid receptor FXR agonist | NR1H4 | Phase 2 | Primary Biliary Cholangitis | Dec 2028 |
Primary Biliary Cholangitis (2) Immune-Mediated Cholestasis (1) Acute Pancreatitis Due to Gallstones (1) Colitis, Ulcerative (1) Crohn Disease (1) Gastric Intestinal Metaplasia (1) Non Alcoholic Fatty Liver Diseases (NAFLD) (1) Non-alcoholic Steatohepatitis (1) Kidney Cancer (1) Primary Biliary Cholangitis (PBC) (1) Barrett Esophagus (1)
small molecule (9), mixed (1), protein or peptide (1)
University Hospital, Montpellier (1) Hospital General Universitario de Alicante (1) Gilead Sciences (1) Eli Lilly (1) Yongquan Shi (1) Ain Shams University (1) Peking Union Medical College Hospital (1) Tanta University (1) Jinling Hospital, China (1) Xijing Hospital of Digestive Diseases (1) National Cancer Institute (NCI) (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.